Related Experiment Video
Updated: Sep 26, 2026
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Studies with ZD1839 in preclinical models
1Laboratory for Molecular Therapeutics, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is an orally active, selective inhibitor of epidermal growth factor receptor-tyrosine kinase (EGFR-TK) that blocks signaling pathways responsible for driving proliferation, invasion, and survival of cancer cells. In preclinical studies of cell lines and human tumor xenografts, ZD1839 as single-agent therapy produced growth inhibition in a wide variety of common solid tumor types including lung, prostate, breast, colon, and ovarian cancers. In these models, ZD1839 inhibited growth of tumor xenografts with high, moderate, and low expression of EGFR. The A431 vulvar carcinoma model, which expresses abnormally high levels of EGFR, was particularly sensitive to ZD1839 treatment, leading to tumor regression. When ZD1839 was coadministered with cytotoxic chemotherapy agents or radiotherapy, additive or even synergistic antitumor activity was achieved. The inhibition observed with ZD1839 treatment was not restricted to advanced metastatic tumors, but also extended to early lesions such as breast xenografts of human ductal carcinoma in situ. Inhibition of EGFR-TK has also been shown to delay the onset of tumor development in a transgenic animal model. The diverse and profound antitumor activities attained with ZD1839 treatment in tumor cells and in xenograft tumor models provided the rationale for clinical development of ZD1839. Ongoing preclinical studies continue to support the importance of EGFR-TK activity in the biology of solid tumors.
Insights
ZD1839 (Iressa) is a targeted therapy inhibiting epidermal growth factor receptor-tyrosine kinase (EGFR-TK). This drug demonstrated significant antitumor activity across various solid tumors in preclinical models, supporting its clinical development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor-tyrosine kinase (EGFR-TK) signaling pathways drive cancer cell proliferation, invasion, and survival.
- Selective inhibition of EGFR-TK represents a promising therapeutic strategy for solid tumors.
Purpose of the Study:
- To evaluate the preclinical antitumor activity of ZD1839 (Iressa), a selective EGFR-TK inhibitor.
- To assess the efficacy of ZD1839 as a single agent and in combination with chemotherapy or radiotherapy.
Main Methods:
- Preclinical studies using cancer cell lines and human tumor xenografts.
- Assessment of ZD1839's effect on tumor growth inhibition and regression across various solid tumor types.
- Evaluation of combination therapy with cytotoxic agents or radiotherapy.
Main Results:
- ZD1839 demonstrated growth inhibition in lung, prostate, breast, colon, and ovarian cancer xenografts, irrespective of EGFR expression levels.
- A431 vulvar carcinoma xenografts, with high EGFR expression, showed tumor regression.
- Combination therapy with ZD1839 resulted in additive or synergistic antitumor activity.
- Inhibition of EGFR-TK delayed tumor development in a transgenic model and affected early-stage lesions.
Conclusions:
- ZD1839 exhibits broad-spectrum preclinical antitumor activity against solid tumors.
- Targeting EGFR-TK with ZD1839 is a viable strategy for cancer therapy, including early-stage disease.
- Further clinical investigation of ZD1839 is warranted based on its diverse and potent preclinical effects.
